|Table of Contents|

The utility of liquid biopsy in NSCLC

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2017 01
Page:
160-164
Research Field:
Publishing date:

Info

Title:
The utility of liquid biopsy in NSCLC
Author(s):
Shen Xiaoyan; Zhang Hang; Yang Yang; Wang Lifeng
Cancer Center of Drum-Tower Hospital，Medical School of Nanjing University，Clinical Cancer Institute of Nanjing University，Jiangsu Nanjing 210008，China．
Keywords:
liquid biopsy; none small cell lung cancer; circulating tumor cell; cell-free DNA; Exosomes
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2017.01.044
Abstract:
With the rapid development of precision medicine and individual therapy in lung cancer，the demand for real-time monitoring of tumor molecular characteristic has been increased."Liquid biopsy" has attracted extensive attention for its convenience，minimal invasiveness and high reproducibility in recent years.About 85%~90% of lung cancer patients are identified as NSCLC，the treatment decision of NSCLC has been changed a lot since the discovery of driver mutations and the successful application of targeted therapy，especially in lung adenocarcinoma.Meanwhile higher demand for real-time monitoring of molecular biomarkers in NSCLC is required.This review discusses the detection of biomarkers in liquid biopsy and its clinical application in NSCLC patients.

References:

［1］Rolfo C，Castiglia M，Hong D，et al.Liquid biopsies in lung cancer：the new ambrosia of researchers［J］.Biochim Biophys Acta，2014，1846(2)：539-546.
［2］Paget S.The distribution of secondary growths in cancer of the breast［J］.Lancet，1889，133：571-573.
［3］Sleijfer S，Gratama JW，Sieuwerts AM，et al.Circulating tumour cell detection on its way to routine diagnostic implementation［J］?Eur J Cancer，2007，43(18)：2645-2650.
［4］Paterlini-Brechot P，Benali NL.Circulating tumor cells(CTC）detection：clinical impact and future directions［J］.Cancer Lett，2007，253(2)：180-204.
［5］Tibbe AG，Miller MC，Terstappen LW.Statistical considerations for enumeration of circulating tumor cells［J］.Cytometry A，2007，71(3)：154-162.
［6］Chen X，Zhou F，Li X，et al.Folate receptor-positive circulating tumor cell detected by LT-PCR-based method as a diagnostic biomarker for non-small-cell lung cancer［J］.J Thorac Oncol，2015，10(8)：1163-1171.
［7］Allard WJ，Matera J，Miller MC，et al.Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases［J］.Clin Cancer Res，2004，10(20)：6897-6904.
［8］Krebs MG，Sloane R，Priest L，et al.Evaluation and prognostic significance of circulating tumor cells in patients with non-small-cell lung cancer［J］.J Clin Oncol，2011，29(12)：1556-1563.
［9］Krebs MG，Hou JM，Sloane R，et al.Analysis of circulating tumor cells in patients with non-small cell lung cancer using epithelial marker-dependent and-independent approaches［J］.J Thorac Oncol，2012，7(2)：306-315.
［10］Yu N，Zhou J，Cui F，et al.Circulating tumor cells in lung cancer：detection methods and clinical applications［J］.Lung，2015，193(2)：157-171.
［11］Ilie M，Hofman V，Long E，et al.Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids，and their characterization in non-small cell lung carcinoma patients.What is the best blood substrate for personalized medicine［J］?Ann Transl Med，2014，2(11)：107.
［12］Nie K，Jia Y，Zhang X.Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer［J］.Tumour Biol，2015，36(1)：7-19.
［13］De Biase D，Visani M，Malapelle U，et al.Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples(cytology and biopsy)［J］.PLoS One，2013，8(12)：e83607.
［14］Rodriguez M，Silva J，Lopez-Alfonso A，et al.Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer［J］.Genes Chromosomes Cancer，2014，53(9)：713-724.
［15］Taverna S，Giallombardo M，Gil-Bazo I，et al.Exosomes isolation and characterization in serum is feasible in non-small cell lung cancer patients：critical analysis of evidence and potential role in clinical practice［J］.Oncotarget，2016，7(19)：28748-28760.
［16］Huang SH，Li Y，Zhang J，et al.Epidermal growth factor receptor-containing Exosomes induce tumor-specific regulatory T cells［J］.Cancer Invest，2013，31(5)：330-335.
［17］Siegel R，Ward E，Brawley O，et al.Cancer statistics，2011：the impact of eliminating socioeconomic and racial disparities on premature cancer deaths［J］.CA Cancer J Clin，2011，61(4)：212-236.
［18］Chen YY，Xu GB.Effect of circulating tumor cells combined with negative enrichment and CD45-FISH identification in diagnosis，therapy monitoring and prognosis of primary lung cancer［J］.Med Oncol，2014，31(12)：240.
［19］Szpechcinski A，Chorostowska-Wynimko J，Struniawski R，et al.Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease［J］.Br J Cancer，2015，113(3)：476-483.
［20］Yamashita T，Kamada H，Kanasaki S，et al.Epidermal growth factor receptor localized to exosome membranes as a possible biomarker for lung cancer diagnosis［J］.Pharmazie，2013，68(12)：969-973.
［21］Rabinowits G，Gerel-Taylor C，Day JM，et al.Exosomal microRNA：A diagnostic marker for lung cancer［J］.Clinical Lung Cancer，2009，10(1)：42-46.
［22］Maheswaran S，Sequist LV，Nagrath S，et al.Detection of mutations in EGFR in circulating lung-cancer cells［J］.N Engl J Med，2008，359(4)：366-377.
［23］Mok T，Wu YL，Lee JS，et al.Detection and dynamic changes of egfr mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy［J］.Clin Cancer Res，2015，21(14)：3196-3203.
［24］Thress KS，Paweletz CP，Felip E，et al.Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M［J］.Nat Med，2015，21(6)：560-562.
［25］Zhang Z，Xiao Y，Zhao J，et al.Relationship between circulating tumour cell count and prognosis following chemotherapy in patients with advanced non-small-cell lung cancer［J］.Respirology，2016，21(3)：519-525.
［26］Lee JY，Qing X，Xiumin W，et al.Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs：Korean Lung Cancer Consortium(KLCC-12-02)［J］.Oncotarget，2016，7(6)：6984-6993.
［27］Karachaliou N，Mayo-de las Casas C，Queralt C，et al.Association ofEGFRL858R mutation in circulating free DNA with survival in the eurtac trial［J］.JAMA Oncology，2015，1(2)：149.
［28］Gorges TM，Penkalla N，Schalk T，et al.Enumeration and molecular characterization of tumor cells in lung cancer patients using a novel in vivo device for capturing circulating tumor cells［J］.Clin Cancer Res，2016，22(9)：2197-2206.
［29］Sundaresan TK，Sequist LV，Heymach JV，et al.Detection of T790M，the acquired resistance EGFR mutation，by tumor biopsy versus noninvasive blood-based analyses［J］.Clin Cancer Res，2016，22(5)：1103-1110.

Memo

Memo:
-
Last Update: 2016-12-01